ArticleJournal for immunotherapy of cancer2025

Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v.

Hana Matuskova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.